[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2001255260A1 - Macroaggregated protein conjugates as oral genetic immunization delivery agents - Google Patents

Macroaggregated protein conjugates as oral genetic immunization delivery agents

Info

Publication number
AU2001255260A1
AU2001255260A1 AU2001255260A AU5526001A AU2001255260A1 AU 2001255260 A1 AU2001255260 A1 AU 2001255260A1 AU 2001255260 A AU2001255260 A AU 2001255260A AU 5526001 A AU5526001 A AU 5526001A AU 2001255260 A1 AU2001255260 A1 AU 2001255260A1
Authority
AU
Australia
Prior art keywords
macroaggregated
protein conjugates
delivery agents
genetic immunization
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001255260A
Inventor
Balbir S. Bhogal
Berma M. Kinsey
Frank M. Orson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of AU2001255260A1 publication Critical patent/AU2001255260A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2001255260A 2000-04-07 2001-04-06 Macroaggregated protein conjugates as oral genetic immunization delivery agents Abandoned AU2001255260A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19568000P 2000-04-07 2000-04-07
US60195680 2000-04-07
PCT/US2001/011372 WO2001076643A1 (en) 2000-04-07 2001-04-06 Macroaggregated protein conjugates as oral genetic immunization delivery agents

Publications (1)

Publication Number Publication Date
AU2001255260A1 true AU2001255260A1 (en) 2001-10-23

Family

ID=22722325

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001255260A Abandoned AU2001255260A1 (en) 2000-04-07 2001-04-06 Macroaggregated protein conjugates as oral genetic immunization delivery agents

Country Status (3)

Country Link
US (1) US6821955B2 (en)
AU (1) AU2001255260A1 (en)
WO (1) WO2001076643A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8258288B2 (en) * 2002-02-20 2012-09-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
US20040009903A1 (en) * 2002-05-31 2004-01-15 Tripp Ralph A. Macroaggregated albumin-polyethyleneimine (MAA-PEI) lung-targeted delivery of respiratory syncytial virus DNA vaccines
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
US20060244186A1 (en) * 2005-03-04 2006-11-02 John Wells Cargo lifting platform
US20090041567A1 (en) * 2005-03-04 2009-02-12 John Wells Cargo Lifting Platform
WO2006133099A2 (en) * 2005-06-03 2006-12-14 The Cbr Institute For Biomedical Research, Inc. Sirna microbicides for preventing and treating viral diseases
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
EP1989326A4 (en) 2006-01-17 2009-09-30 Health Research Inc Heteroduplex tracking assay
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2796457C (en) 2010-04-21 2018-08-28 Damon K. Getman Compositions, methods and kits to detect herpes simplex virus nucleic acids
RS57397B8 (en) 2011-06-10 2020-01-31 Univ Oregon Health & Science Cmv glycoproteins and recombinant vectors
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
JP6220389B2 (en) * 2012-05-23 2017-10-25 ジ・オハイオ・ステート・ユニバーシティ Lipid nanoparticle compositions for delivering antisense oligonucleotides
ES2631608T3 (en) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Env-glycoprotein variant of HIV-1
EP2903652B1 (en) * 2012-10-05 2022-04-20 BioNTech Delivery Technologies GmbH Hydroxylated polyamine derivatives as transfection reagents
ES2902839T3 (en) * 2012-10-08 2022-03-30 Biontech Delivery Tech Gmbh Carboxylated polyamine derivatives as transfection reagents
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069352A (en) * 1976-07-02 1978-01-17 Baxter Travenol Laboratories, Inc. Immunoadsorbent polymeric material and method of making same
US6348449B1 (en) * 1993-09-21 2002-02-19 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
US5703057A (en) * 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization

Also Published As

Publication number Publication date
WO2001076643A1 (en) 2001-10-18
US20030165476A1 (en) 2003-09-04
US6821955B2 (en) 2004-11-23

Similar Documents

Publication Publication Date Title
AU2001255260A1 (en) Macroaggregated protein conjugates as oral genetic immunization delivery agents
AU7912100A (en) Pharmaceutical composition comprising an antigen
AU2001285143A1 (en) Methods and compositions for targeted delivery
AU2002335613A1 (en) Biochips comprising nucleic acid/protein conjugates
IL153463A0 (en) Pharmaceutical compositions comprising activated antibodies
AU2002239397A1 (en) Drug formulation having improved oral tolerability
AU1951201A (en) Peptide antigens
EP1391209A4 (en) Protein formulations
AU4139801A (en) Controlled delivery of antigens
AU2001240026A1 (en) Camptothecin conjugates
AU2001232020A1 (en) Floating drug delivery composition
IL151909A0 (en) Peptide conjugates for drug delivery
AU2001284444A1 (en) Preparations for oral administration
AU2001251677A1 (en) Curved blower conduit
AU2001250212A1 (en) Rhamm peptide conjugates
AU2001238485A1 (en) Methods and compositions for gene delivery
AU1620099A (en) Ubiquitin-like conjugating protein
AU2001282037A1 (en) Proton-translocating retinal protein
AU7089800A (en) 29 human cancer associated proteins
EP1385556A4 (en) Gastrin-receptor-avid peptide conjugates
AU2002308649A1 (en) Compositions and methods for enhancing drug delivery
AU2002239279A1 (en) Oral nanosphere delivery
AU2452301A (en) Protein methylarginine-specific antibodies
AU2001267541A1 (en) Vaccine composition
AU2001244854A1 (en) Local drug delivery